Abstract
The court of justice confirms that the supply of misleading information in the context of a request for supplementary protection certificates and the withdrawal of a marketing authorisation within the pharmaceutical sector can constitute abuse of dominant position.
Original language | English |
---|---|
Pages (from-to) | 228-232 |
Journal | Journal of European Competition Law & Practice |
Volume | 4 |
Issue number | 3 |
DOIs | |
Publication status | Published - 1 Jan 2013 |